Cybin is on a mission to revolutionize mental healthcare by engineering proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches, working with a network of world-renowned partners and pioneers in the field to create safe and effective tryptamine-based therapies. The company aims to prove its formulation offers improved benefits compared to orally administered capsules, potentially gaining a competitive edge despite lacking first-mover advantage.
Cyborg Score Rationale
Cybin's lead program CYB003 is in Phase 3 development with a clear path toward approval and eventual commercialization of psychedelic therapeutics gaining clarity. The company has expanded its intellectual property portfolio to over 90 granted patents and over 230 pending applications. However, clinical-stage status and regulatory uncertainties present material risks.
Top Insights
Cybin began trading on the New York Stock Exchange in January 2026, becoming the first psychedelics company on the NYSE and following a trend of five psychedelics companies debuting on Nasdaq since the beginning of the year.
CYB003 is in phase 3 clinical trial for treating major depressive disorder (MDD), and CYB004 is in phase 2 clinical trial for treating generalized anxiety disorders.
Cybin is leveraging Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline.
The addressable markets for depression, anxiety and alcohol use disorder impact approximately 700-800 million people globally with huge unmet needs.
Named Competitors
Compass Therapeutics — Psychedelic-assisted therapy for mental health using psilocybin
Psilocybin Therapy Program — Nonprofit advancing psilocybin research for depression and mental health
Clinical Infrastructure Network — Mental health service centers supporting psychedelic clinical research
Recent Developments
(June 2025) Expanded intellectual property portfolio with two additional U.S. patents supporting CYB003 and CYB004, bringing total to over 90 granted patents and 230+ pending applications
(January 2026) NYSE listing as first psychedelics company on major U.S. exchange
(November 2025) Chief Business Officer presentation at Jefferies Global Healthcare Conference
Open the full interactive Cybin Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.